Targeting BET bromodomain proteins in solid tumors
View/ Open
Author
Sahai, Vaibhav
Collier, Katharine A.
Eckerdt, Frank D.
Munshi, Hidayatullah G.
Published Version
https://doi.org/10.18632/oncotarget.9804Metadata
Show full item recordCitation
Sahai, Vaibhav, Amanda J. Redig, Katharine A. Collier, Frank D. Eckerdt, and Hidayatullah G. Munshi. 2016. “Targeting BET bromodomain proteins in solid tumors.” Oncotarget 7 (33): 53997-54009. doi:10.18632/oncotarget.9804. http://dx.doi.org/10.18632/oncotarget.9804.Abstract
There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins and cancer progression. BET inhibitors were initially shown to have efficacy in hematologic malignancies; however, a number of studies have now shown that BET inhibitors can also block progression of non-hematologic malignancies. In this Review, we summarize the efficacy of BET inhibitors in select solid tumors; evaluate the role of BET proteins in mediating resistance to current targeted therapies; and consider potential toxicities of BET inhibitors. We also evaluate recently characterized mechanisms of resistance to BET inhibitors; summarize ongoing clinical trials with these inhibitors; and discuss potential future roles of BET inhibitors in patients with solid tumors.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288238/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:31731792
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)